Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs for Dermatomyositis have a 60% phase transition success ...

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

CR-4056 is under clinical development by Rottapharm Biotech and currently in Phase II for Osteoarthritis Pain.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Acute Coronary Syndrome.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure.

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...